{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:18:30Z","timestamp":1790849910838,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.pcad.2007.12.003","type":"journal-article","created":{"date-parts":[[2008,5,10]],"date-time":"2008-05-10T05:14:53Z","timestamp":1210396493000},"page":"420-438","source":"Crossref","is-referenced-by-count":26,"title":["Sudden Cardiac Death and the Role of Medical Therapy"],"prefix":"10.1016","volume":"50","author":[{"given":"Aysha","family":"Arshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Mandava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Musat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2007.12.003_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/13543784.16.5.605","article-title":"Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death","volume":"16","author":"Boriani","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pcad.2007.12.003_bib2","first-page":"I2","article-title":"Sudden cardiac death. Structure, function, and time-dependence of risk","volume":"85","author":"Myerburg","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib3","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/01.CIR.0000129322.97266.F3","article-title":"Implantable defibrillators and sudden cardiac death","volume":"109","author":"Josephson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib4","series-title":"Sudden cardiac death: a handbook for clinical practice","first-page":"3","article-title":"Chapter 1: epidemiology of cardiac arrest","author":"Myerburg","year":"2006"},{"key":"10.1016\/j.pcad.2007.12.003_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10840-006-9069-6","article-title":"Sudden cardiac death: epidemiologic and financial worldwide perspective","volume":"17","author":"Smith","year":"2006","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib6","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1161\/hc4301.098254","article-title":"Sudden cardiac death in the United States, 1989 to 1998","volume":"104","author":"Zheng","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.7326\/0003-4819-119-12-199312150-00006","article-title":"Sudden cardiac death: epidemiology, transient risk, and intervention assessment","volume":"119","author":"Myerburg","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib8","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1053\/euhj.2001.2824","article-title":"Task force on sudden cardiac death of the European Society of Cardiology","volume":"22","author":"Priori","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.12.003_bib9","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S0735-1097(97)00355-0","article-title":"Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival","volume":"30","author":"de Vreede-Swagemakers","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib10","first-page":"81","article-title":"Sudden death of adults in Japan","volume":"59","author":"Toyoshima","year":"1996","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.pcad.2007.12.003_bib11","first-page":"1127","article-title":"Incidence rate of sudden death in Japan","volume":"36","author":"Kawakubo","year":"2005","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.pcad.2007.12.003_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/euhj.1998.1189","article-title":"Sudden death in the working population: a collaborative study in central Japan","volume":"20","author":"Kawamura","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.12.003_bib13","series-title":"Heart disease: a textbook of cardiovascular medicine","first-page":"756","article-title":"Cardiac arrest and sudden cardiac death","author":"Myerburg","year":"1992"},{"key":"10.1016\/j.pcad.2007.12.003_bib14","doi-asserted-by":"crossref","first-page":"10F","DOI":"10.1016\/S0002-9149(97)00477-3","article-title":"Frequency of sudden cardiac death and profiles of risk","volume":"80","author":"Myerburg","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1540-8159.1994.tb01413.x","article-title":"Empiric therapy with beta-blockers","volume":"17","author":"Hjalmarson","year":"1994","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib16","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/0002-9149(83)90368-5","article-title":"Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold","volume":"51","author":"Anderson","year":"1983","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.pcad.2007.12.003_bib17","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1177\/10742484050100i403","article-title":"Antiarrhythmic action of beta-blockers: potential mechanisms","volume":"10","author":"Dorian","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.pcad.2007.12.003_bib18","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1177\/10742484050100i402","article-title":"Beta-adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview","volume":"10","author":"Singh","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pcad.2007.12.003_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/oxfordjournals.eurheartj.a060043","article-title":"Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials","volume":"13","author":"Olsson","year":"1992","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.12.003_bib20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(82)92225-5","article-title":"Controlled trial of sotalol for one year after myocardial infarction","volume":"1","author":"Julian","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib22","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1001\/jama.250.20.2814","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results","volume":"250","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.12.003_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(02)92899-0","article-title":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group","volume":"2","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0140-6736(65)90863-9","article-title":"Effect of propranolol in myocardial infarction","volume":"2","author":"Snow","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","article-title":"Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial","volume":"2","author":"Hjalmarson","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oxfordjournals.eurheartj.a061845","article-title":"A randomised placebo-controlled international trial. The MIAMI Trial Research Group","volume":"6","author":"Metoprolol in acute myocardial infarction (MIAMI)","year":"1985","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.12.003_bib27","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"beta-Blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2007.12.003_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2004.09.076","article-title":"Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial","volume":"45","author":"McMurray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/01.CIR.83.2.422","article-title":"Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study","volume":"83","author":"Roberts","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"The GUSTO investigators","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0002-9149(02)03401-X","article-title":"Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction","volume":"91","author":"Harjai","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib33","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jacc.2003.09.071","article-title":"Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty?","volume":"43","author":"Kernis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1034\/j.1600-6143.2003.08062.x","article-title":"Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials","volume":"16","author":"Ellis","year":"2003","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib35","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2003.10.068","article-title":"Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction","volume":"43","author":"Halkin","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0735-1097(02)02013-2","article-title":"Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention","volume":"40","author":"Chan","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib37","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0735-1097(01)01225-6","article-title":"Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma","volume":"37","author":"Chen","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.eurheartj.a059591","article-title":"Diabetic patients and beta-blockers after acute myocardial infarction","volume":"11","author":"Kjekshus","year":"1990","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.12.003_bib39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0008-6363(96)00263-5","article-title":"Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study","volume":"34","author":"Malmberg","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2007.12.003_bib40","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-131-9-199911020-00003","article-title":"Early beta-blocker therapy for acute myocardial infarction in elderly patients","volume":"131","author":"Krumholz","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib41","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib42","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM200105033441803","article-title":"Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure","volume":"344","author":"Yancy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib43","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.94.11.2800","article-title":"Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group","volume":"94","author":"Colucci","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.surg.2005.03.022","article-title":"A meta-analysis of perioperative beta blockade: what is the actual risk reduction?","volume":"138","author":"McGory","year":"2005","journal-title":"Surgery"},{"key":"10.1016\/j.pcad.2007.12.003_bib45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.38503.623646.8F","article-title":"How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials","volume":"331","author":"Devereaux","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2007.12.003_bib46","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.287.17.2221","article-title":"Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America","volume":"287","author":"Ferguson","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.12.003_bib47","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jacc.2006.02.028","article-title":"ACC\/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology","volume":"47","author":"Fleisher","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib48","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees","volume":"90","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib50","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib51","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib52","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.CIR.87.2.312","article-title":"Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results","volume":"87","author":"Maggioni","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib55","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1093\/eurheartj\/ehi386","article-title":"Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial","volume":"26","author":"Metra","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.12.003_bib56","first-page":"25","article-title":"The role of beta-blockers in preventing sudden death in heart failure","volume":"6","author":"Teerlink","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2007.12.003_bib57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5414\/CPP39383","article-title":"Beta-blockers and heart failure: meta-analysis of mortality trials","volume":"39","author":"Cleophas","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.pcad.2007.12.003_bib58","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","article-title":"ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib59","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.jacc.2006.07.010","article-title":"ACC\/AHA\/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)","volume":"48","author":"Zipes","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib60","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib61","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.22.17","article-title":"Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension","volume":"22","author":"Sato","year":"1999","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pcad.2007.12.003_bib63","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0735-1097(01)01243-8","article-title":"Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure","volume":"37","author":"Yee","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","article-title":"Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients","volume":"35","author":"MacFadyen","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2007.12.003_bib65","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy","volume":"85","author":"Ramires","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib66","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib67","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pcad.2007.12.003_bib68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pcad.2007.12.003_bib69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pcad.2007.12.003_bib70","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","article-title":"Relation of aldosterone \u201cescape\u201d despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"89","author":"Cicoira","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib72","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cardfail.2006.11.016","article-title":"The effect of spironolactone use on heart failure mortality: a population-based study","volume":"13","author":"Ouzounian","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2007.12.003_bib75","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/01.CIR.96.4.1173","article-title":"Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure","volume":"96","author":"Grassi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib76","first-page":"VII49","article-title":"The role of ACE inhibitors in the treatment of arrhythmias","volume":"13","author":"McKenna","year":"1990","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib77","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1046\/j.1540-8167.14.s9.23.x","article-title":"Use of nonantiarrhythmic drugs for prevention of sudden cardiac death","volume":"14","author":"Alberte","year":"2003","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib78","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJM199209033271002","article-title":"Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)","volume":"327","author":"Swedberg","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib79","first-page":"1115","article-title":"GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib80","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib82","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib83","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting\u2013enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib84","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib85","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib87","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib88","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting\u2013enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib89","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting\u2013enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib90","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2005.11.073","article-title":"Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"Al-Mallah","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib91","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archinte.166.7.787","article-title":"Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials","volume":"166","author":"Danchin","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib92","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib93","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib95","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib96","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.273.18.1450","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.12.003_bib97","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/oxfordjournals.eurheartj.a015425","article-title":"Evaluation of Losartan in the Elderly (ELITE) Trial: clinical implications","volume":"18","author":"Pitt","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2007.12.003_bib98","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib99","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib100","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib101","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib102","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib103","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/0003-4819-141-9-200411020-00011","article-title":"Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction","volume":"141","author":"Lee","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib104","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosissup.2004.08.027","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.pcad.2007.12.003_bib106","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib107","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9149(02)02201-4","article-title":"Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial","volume":"89","author":"Cannon","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib108","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/01.CIR.0000086460.55494.AF","article-title":"Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE\u204e3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin","volume":"108","author":"Kleemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib109","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib110","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","article-title":"Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib111","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.12.003_bib112","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.12.003_bib113","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib114","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.0954-6820.1976.tb08198.x","article-title":"The composition of food consumed by Greenland Eskimos","volume":"200","author":"Bang","year":"1976","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.pcad.2007.12.003_bib115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(78)91505-2","article-title":"Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?","volume":"2","author":"Dyerberg","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib116","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0002-8703(88)90328-6","article-title":"Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion","volume":"116","author":"McLennan","year":"1988","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2007.12.003_bib117","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1139\/y85-232","article-title":"Influence of dietary lipids on arrhythmias and infarction after coronary artery ligation in rats","volume":"63","author":"McLennan","year":"1985","journal-title":"Can J Physiol Pharmacol"},{"issue":"Suppl D","key":"10.1016\/j.pcad.2007.12.003_bib118","doi-asserted-by":"crossref","first-page":"D98","DOI":"10.1016\/S1520-765X(01)90127-0","article-title":"The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids","author":"Leaf","year":"2001","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.pcad.2007.12.003_bib119","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00232-005-0789-9","article-title":"Membrane effects of the n-3 fish oil fatty acids, which prevent fatal ventricular arrhythmias","volume":"206","author":"Leaf","year":"2005","journal-title":"J Membr Biol"},{"key":"10.1016\/j.pcad.2007.12.003_bib120","doi-asserted-by":"crossref","first-page":"50i","DOI":"10.1016\/j.amjcard.2005.12.027","article-title":"Antiarrhythmic effects of omega-3 fatty acids","volume":"98","author":"Reiffel","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib121","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1073\/pnas.94.8.4182","article-title":"Suppression of voltage-gated l-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes","volume":"94","author":"Xiao","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl","key":"10.1016\/j.pcad.2007.12.003_bib122","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s11745-001-0691-y","article-title":"The electrophysiologic basis for the antiarrhythmic and anticonvulsant effects of n-3 polyunsaturated fatty acids: heart and brain","volume":"36","author":"Leaf","year":"2001","journal-title":"Lipids"},{"key":"10.1016\/j.pcad.2007.12.003_bib123","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/qjmed\/hcg092","article-title":"The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease","volume":"96","author":"Lee","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.pcad.2007.12.003_bib124","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1472-8206.2006.00438.x","article-title":"Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids","volume":"20","author":"Leaf","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pcad.2007.12.003_bib125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0002-9149(01)02314-1","article-title":"Association between n-3 fatty acid status in blood and electrocardiographic predictors of arrhythmia risk in healthy volunteers","volume":"89","author":"Brouwer","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib126","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/bmj.312.7032.677","article-title":"Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial","volume":"312","author":"Christensen","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2007.12.003_bib127","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0002-9149(97)00220-8","article-title":"Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction","volume":"79","author":"Christensen","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2796.2001.00841.x","article-title":"Heart rate variability and n-3 polyunsaturated fatty acids in patients with diabetes mellitus","volume":"249","author":"Christensen","year":"2001","journal-title":"J Intern Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MOL.0b013e328012d61b","article-title":"Omega-3 fatty acids and prevention of arrhythmias","volume":"18","author":"Leaf","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pcad.2007.12.003_bib130","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/oxfordjournals.aje.a117615","article-title":"Fish consumption and cardiovascular disease in the physicians' health study: a prospective study","volume":"142","author":"Morris","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib131","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jama.279.1.23","article-title":"Fish consumption and risk of sudden cardiac death","volume":"279","author":"Albert","year":"1998","journal-title":"Jama"},{"key":"10.1016\/j.pcad.2007.12.003_bib132","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(89)90828-3","article-title":"Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART)","volume":"2","author":"Burr","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib133","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","article-title":"Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione","volume":"105","author":"Marchioli","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib134","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/CIRCULATIONAHA.105.549527","article-title":"Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake","volume":"112","author":"Leaf","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib135","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.295.22.2613","article-title":"Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial","volume":"295","author":"Brouwer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.12.003_bib136","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1001\/jama.293.23.2884","article-title":"Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial","volume":"293","author":"Raitt","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2007.12.003_bib137","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10557-006-0495-6","article-title":"Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction\u2014aims and methods of the OMEGA study","volume":"20","author":"Rauch","year":"2006","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pcad.2007.12.003_bib138","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0735-1097(92)90357-S","article-title":"Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study","volume":"20","author":"Ceremuzynski","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib139","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/0735-1097(90)90324-I","article-title":"Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)","volume":"16","author":"Burkart","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2007.12.003_bib140","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(96)09145-3","article-title":"Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators","volume":"349","author":"Julian","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib141","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(96)08171-8","article-title":"Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators","volume":"349","author":"Cairns","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib142","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(94)91895-3","article-title":"Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)","volume":"344","author":"Doval","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib143","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.CIR.96.9.2823","article-title":"Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death","volume":"96","author":"Sim","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2007.12.003_bib144","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(97)05281-1","article-title":"Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2007.12.003_bib145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199507133330201","article-title":"Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure","volume":"333","author":"Singh","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2007.12.003_bib146","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062007001314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062007001314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T03:30:11Z","timestamp":1557545411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062007001314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":146,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0033062007001314"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2007.12.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}